232 related articles for article (PubMed ID: 30615495)
1. The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients.
Scarpa D; Denas G; Babuin L; Pengo V
Expert Opin Pharmacother; 2019 Feb; 20(3):261-268. PubMed ID: 30615495
[TBL] [Abstract][Full Text] [Related]
2. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
Nafee T; Gibson CM; Yee MK; Alkhalfan F; Chi G; Travis R; Mir M; Kalayci A; Jafarizade M; Ganti A; Kazmi SH; Ghaffarpasand E; Pitliya A; Datta S; Sharfaei S; Alihashemi M; Elsaiey A; Qamar I; Jahansouz M; Talib U; Kahe F; Habibi S; Abdelwahed M; Tariq F; Kaur M; Younes A; Walia SS; Singh A; Dildar SM; Afzal MK; Kerneis M
Expert Rev Cardiovasc Ther; 2018 Nov; 16(11):845-855. PubMed ID: 30296387
[TBL] [Abstract][Full Text] [Related]
3. Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
Escolar G; Díaz-Ricart M; Arellano-Rodrigo E
Drugs Today (Barc); 2017 Aug; 53(8):423-434. PubMed ID: 29119147
[TBL] [Abstract][Full Text] [Related]
4. Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.
Lee K; Cham S; Lam S
Cardiol Rev; 2018; 26(6):331-338. PubMed ID: 30067518
[TBL] [Abstract][Full Text] [Related]
5. Overview of betrixaban and its role in clinical practice.
Lekura J; Kalus JS
Am J Health Syst Pharm; 2018 Aug; 75(15):1095-1102. PubMed ID: 29941506
[TBL] [Abstract][Full Text] [Related]
6. Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
Garland SG; DeRemer CE; Smith SM; Gums JG
Ann Pharmacother; 2018 Jun; 52(6):554-561. PubMed ID: 29338293
[TBL] [Abstract][Full Text] [Related]
7. Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
Miller KM; Brenner MJ
Drugs; 2019 Feb; 79(3):291-302. PubMed ID: 30719631
[TBL] [Abstract][Full Text] [Related]
8. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
Chi G; Gibson CM; Kalayci A; Cohen AT; Hernandez AF; Hull RD; Kahe F; Jafarizade M; Sharfaei S; Liu Y; Harrington RA; Goldhaber SZ
Intensive Care Med; 2019 Apr; 45(4):477-487. PubMed ID: 30778649
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.
Laskier V; Guy H; Fisher M; Neuman WR; Bucior I; Cohen AT; Ren S
J Med Econ; 2019 Oct; 22(10):1063-1072. PubMed ID: 31314619
[No Abstract] [Full Text] [Related]
10. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Gibson CM; Halaby R; Korjian S; Daaboul Y; Arbetter DF; Yee MK; Goldhaber SZ; Hull R; Hernandez AF; Lu SP; Bandman O; Leeds JM; Gold A; Harrington RA; Cohen AT;
Am Heart J; 2017 Mar; 185():93-100. PubMed ID: 28267480
[TBL] [Abstract][Full Text] [Related]
11. Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
Ageno W; Lopes RD; Yee MK; Hernandez A; Hull RD; Goldhaber SZ; Gibson CM; Cohen AT
J Thromb Haemost; 2019 Dec; 17(12):2089-2098. PubMed ID: 31392827
[TBL] [Abstract][Full Text] [Related]
12. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Gibson CM; Chi G; Halaby R; Korjian S; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Gold A; Bandman O; Harrington RA; Cohen AT;
Circulation; 2017 Feb; 135(7):648-655. PubMed ID: 27881569
[TBL] [Abstract][Full Text] [Related]
13. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
14. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
[TBL] [Abstract][Full Text] [Related]
15. Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis.
Dobesh PP; Trevarrow BJ
Am J Med; 2019 Mar; 132(3):307-311. PubMed ID: 30201249
[TBL] [Abstract][Full Text] [Related]
16. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
Cohen AT; Harrington RA; Goldhaber SZ; Hull RD; Wiens BL; Gold A; Hernandez AF; Gibson CM;
N Engl J Med; 2016 Aug; 375(6):534-44. PubMed ID: 27232649
[TBL] [Abstract][Full Text] [Related]
17. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients.
Cave B; Hough A; Dobesh PP
Pharmacotherapy; 2018 Jun; 38(6):597-609. PubMed ID: 29543384
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Gibson CM; Korjian S; Chi G; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Lopes RD; Gold A; Cohen AT; Harrington RA;
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28698258
[TBL] [Abstract][Full Text] [Related]
19. Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy.
Chi G; Gibson CM; Hernandez AF; Hull RD; Kazmi SHA; Younes A; Walia SS; Pitliya A; Singh A; Kahe F; Kalayci A; Nafee T; Kerneis M; AlKhalfan F; Cohen AT; Harrington RA; Goldhaber SZ
Am J Med; 2018 Aug; 131(8):972.e1-972.e7. PubMed ID: 29660351
[TBL] [Abstract][Full Text] [Related]
20. Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes.
Ageno W
Intern Emerg Med; 2018 Oct; 13(7):1009-1013. PubMed ID: 28808888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
